In this article

NVO

NOVO.B-DK

Follow your favorite stocks CREATE FREE ACCOUNT

Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid intense competition in the obesity drug market.

Novo on Wednesday said it would cut 9,000 jobs after sales growth had stalled and shares had slumped, knocking $450 billion off the company's market cap since the middle of last year, as it faces competition from U.S. rival Eli Lilly and a wave of compounded copycat drugs.

"This is designed to foster a stronger sense of belonging, strengthen relationships, enhance collaboration and accelerate decision-making processes," the company said in a st

See Full Page